Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography–mass spectrometry after solid-phase extraction
- 5 October 2004
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 809 (2), 217-226
- https://doi.org/10.1016/j.jchromb.2004.06.023
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteersPharmacogenetics, 2004
- Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially PhenprocoumonSeminars in Thrombosis and Hemostasis, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Development and validation of a high-performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 1993
- Metabolic Fate of Phenprocoumon in HumansJournal of Pharmaceutical Sciences, 1985
- A stable isotope assay for phenprocoumon and its metabolitesJournal of Mass Spectrometry, 1985
- Stereospecific Fluorescence High-Performance Liquid Chromatographic Analysis of Warfarin and its Metabolites in Plasma and UrineJournal of Pharmaceutical Sciences, 1984
- Synthesis and thin-layer chromatographic, ultraviolet, and mass spectral properties of the anticoagulant phenprocoumon and its monohydroxylated derivativesJournal of Medicinal Chemistry, 1975
- THE METABOLIC FATE OF WARFARIN: STUDIES ON THE METABOLITES IN PLASMA*Annals of the New York Academy of Sciences, 1971
- Warfarin metabolism in man: identification of metabolites in urineJCI Insight, 1970